Sensus Healthcare Inc Stock News

While people tend to avoid price hikes, certain stocks up 100% this year just might provide an exception to the rule. Basically, not even two months have passed by.

MSGE, AZEK, XRX, AMSC and SRTS have been added to the Zacks Rank #1 (Strong Buy) List on February 12, 2023.

Sensus Healthcare, Inc. (SRTS) Q4 2023 Earnings Call Transcript

Sensus Healthcare, Inc. (SRTS) came out with quarterly earnings of $0.26 per share, beating the Zacks Consensus Estimate of $0.12 per share. This compares to earnings of $0.17 per share a year ago.

BOCA RATON, Fla. , Jan. 30, 2024 (GLOBE NEWSWIRE) -- Sensus Healthcare, Inc. (Nasdaq: SRTS), a medical device company specializing in highly effective, non-invasive treatments for both oncological and

Sensus Healthcare, Inc. (SRTS) Q3 2023 Earnings Call Transcript

BOCA RATON, Fla, Nov. 02, 2023 (GLOBE NEWSWIRE) -- Sensus Healthcare, Inc. (Nasdaq: SRTS), a medical device company specializing in highly effective, non-invasive treatments for both oncological and n

While the health innovation space presents wild risks, you could potentially swing the odds in your favor with strong buy biotech stocks. Specifically, these ideas represent publicly traded biotechnol

Sensus Healthcare, Inc (NASDAQ:SRTS ) Q2 2023 Earnings Conference Call August 3, 2023 4:30 PM ET Company Participants Kim Golodetz - IR Joseph Sardano - Chairman and CEO Michael Sardano - President an

Sensus Healthcare, Inc. (SRTS) came out with a quarterly loss of $0.02 per share versus the Zacks Consensus Estimate of a loss of $0.05. This compares to earnings of $0.21 per share a year ago.

Although there's some merit in assuming that strength may beget more strength, targeting undervalued stocks may represent a more sensible option at the moment. With the Federal Reserve mulling a possi

The agreement includes the distribution of Sensus Healthcare's (SRTS) SRT-100, SRT-100+ and SR-100 Vision systems, specifically designed for the treatment of non-melanoma skin cancer and keloids.

Generally speaking, you get what you pay for, which is why the concept of affordable sleeper stocks to buy might not immediately seem so attractive. However, the market arguably doesn't perfectly valu

Sensus Healthcare, Inc. (SRTS) came out with a quarterly loss of $0.12 per share versus the Zacks Consensus Estimate of $0.11. This compares to earnings of $0.20 per share a year ago.

While the adage that you get what you pay for generally rings true, you can sometimes cheat up this narrative with the best stocks to buy under $10. While you can't get much for a Hamilton these days,